Life-habit intervention in a public institution;Intervenção nos hábitos de vida em instituiç ão pública

Arquivos Brasileiros de Cardiologia

Volumn 94, Issue 6, 2010, Pages 730-737

  Scherr, Carlos ^a   Da Cunha, Ademir Batista ^a   Magalhães, Chyntia Karla ^a   Abitibol, Rafael Aron ^a   Barros, Marcelo ^a   Cordovil, Ivan ^a  

^a INSTITUTO NACIONAL DE CARDIOLOGIA   (Brazil)

Author keywords

Atheroclerosis; Coronary heart disease; Risk factors; Secondary prevention

Indexed keywords

CHOLESTEROL; LOW DENSITY LIPOPROTEIN; TRIACYLGLYCEROL;

ADULT; ANGIOCARDIOGRAPHY; ARTICLE; ATHEROSCLEROSIS; BODY MASS; CHOLESTEROL BLOOD LEVEL; CORONARY ARTERY DISEASE; DIET; FEMALE; HEALTH CARE; HEALTH PROGRAM; HUMAN; HYPOLIPEMIA; LIPOPROTEIN BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; PHYSICAL ACTIVITY; PUBLIC HEALTH; RISK FACTOR; SITTING; SMOKING; SOCIOECONOMICS; TRIACYLGLYCEROL BLOOD LEVEL; WAIST CIRCUMFERENCE;

ADULT; AGED; AGED, 80 AND OVER; BRAZIL; CHOLESTEROL; CORONARY ARTERY DISEASE; CROSS-SECTIONAL STUDIES; FEMALE; HEALTH STATUS; HUMANS; LIFE STYLE; MALE; MIDDLE AGED; OUTCOME ASSESSMENT (HEALTH CARE); PATIENT-CENTERED CARE; RISK FACTORS; SECONDARY PREVENTION; TIME FACTORS; TREATMENT OUTCOME;

EID: 77955600019     PISSN: 0066782X     EISSN: 16784170     Source Type: Journal    
DOI: 10.1590/S0066-782X2010005000058     Document Type: Article

References (21)

1. World Health Organization (WHO). Global burden of coronary heart disease (on line). [Acesso em 2008 out 10]. Disponível em: http://www.who.int/ cardiovascular-disease/en/cvd-atlas-13-coronaryhd.pdf.
2. Ministério da Saúde. Datasus. [Acesso em 2008 out 7]. Disponível em: http://tabnet.datasus.gov.br/cgi/tabcgi.exe?idb2007/c04. def
3. Romero T. Cardiac rehabilitation as a first step in the secondary prevention of coronary heart disease. Rev Med Chil. 2000; 128 (8): 923-34.
4. McAlister FA, Lawson FM, Teo KK, Armstrong PW. Randomised trials of secondary prevention programmes in coronary heart disease: systematic review. BMJ. 2001; 323 (7319): 957-62.
5. Pirich C, Bisovsky S, Sinzinger H. Economic aspects of therapy for lipid metabolism disorders. Wien Klin Wochesnschr. 1992; 104 (14): 401-8.
6. Ornish D, Brown SE, Sherwitz LW, Billings JH, Armstrong WT, Ports TA, et al. Can lifestyle changes reverse coronary heart disease? The Lifestyle Heart Trial. Lancet. 1990; 336 (8708): 129-33.
7. Colquhoun DM. Lipid lowering agents: how important are they in secondary prevention of coronary heart disease? Aust Fam Physician. 2002; 31 (1): 25-6, 29-30.
8. Pedersen TR, Kjekshus J, Pyörälä K, Olsson AG, Cook TJ, Musliner TA, et al. Effects of simvastatin on ischemic signs and symptoms in the Scandinavian simvastatin survival study (4S). Am J Cardiol. 1998; 81 (3): 333-5. (Pubitemid 28099310)
9. Sacks FM, Pfeffer MA, Moye LA, Rouleau JL, Rutherford JD, Cole TG, et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N Engl J Med. 1996; 335 (14): 1001-9.
10. Tonkin A. The long-term intervention with pravastatin in ischaemic disease (LIPID) study group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and broad range of initial cholesterol levels. N Engl J Med. 1998; 339 (19): 1349-57.
11. Kotseva K, Wood D, De Backer G, De Bacquer D, Pyörälä K, Keil U, EUROASPIRE Study Group. Cardiovascular prevention guidelines in daily practice: a comparison of EUROASPIRE I, II, and III surveys in eight European countries. Lancet. 2009; 373 (9667): 929-40.
12. Murchie P, Campbell NC, Ritchie LD, Simpson JA, Thain J. Secondary prevention clinics for coronary heart disease: four year follow up of a randomised controlled trial in primary care. BMJ. 2003; 326 (7380): 84.
13. Sheperd J, Cobbe SM, Ford I, Isles CG, Lorimer AR, Macfarlane PW, et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. The West of Scotland Coronary Prevention Study Group. N Engl J Med. 1995; 333 (20): 1301-7.
14. Ornish D, Scherwitz LW, Billings JH, Gould KL, Merritt TA, Sparler S, et al. Intensive lifestyle changes for reversal of coronary heart disease. JAMA. 1998; 280 (23): 2001-7. (Pubitemid 28562678)
15. Rutledge JC, Hyson DA, Garduno D, Cort DA, Paumer L, Kappagoda CT. Lifestyle modification program in management of patients with coronary artery disease: the clinical experience in a tertiary care hospital. J Cardiopulm Rehabil. 1999: 19 (4): 226-34. (Pubitemid 29380303)
16. Watts GF, Lewis B, Brunt JN, Lewis ES, Coltart DJ, Smith LD, et al. Effects on coronary artery disease of lipid-lowering diet, or d-plus cholestyramine, in the St. Thomas Atherosclerosis Regression Study (STARS). Lancet. 1992; 339 (8793): 563-9.
17. Lorgeril M, Renaud S, Mamelle N, Salen P, Martin JL, Monjaud I, et al. Mediterranean alpha-linolenic acid-rich diet in secondary prevention of coronary heart disease. Lancet. 1994; 343 (8911): 1454-9. (Pubitemid 24176333)
18. de Lorgeril M, Salen P, Martin JL, Monjaud I, Delaye J, Mamelle N. Mediterranean diet, traditional risk factors, and the rate of cardiovascular complications after myocardial infarction: final report of the Lyon Diet Heart Study. Circulation. 1999; 99 (6): 779-85. (Pubitemid 29083018)
19. Leaf A. Dietary prevention of coronary heart disease: the Lyon Diet Heart Study. Circulation. 1999; 99 (6): 733-5. (Pubitemid 29083011)
20. Ladeia AM, Guimarães AC. Assessment of risk factors in coronary patients being followed by cardiologists: control of risk factors in coronary patients Prev Cardiol. 2003; Summer; 6 (3): 122-7
21. Mendis S, Abegunde D, Yusuf S, Ebrahim S, Shaper G, Ghannem H, et al. WHO study on Prevention of REcurrences of Myocardial Infarction and StrokE (WHO-PREMISE). Bull World Health Organ. 2005; 83 (11): 820-9.